

MiyaHealth Pte Ltd

Disclosure Report Date Submitted: February 26th, 2024

© B Lab 2023



Disclosure Materials

Certified B Corporations must complete a Disclosure Questionnaire to identify potentially sensitive issues related to the company (e.g. historical fines, sanctions, material litigation, or sensitive industry practices).

This component does not affect the company's score on the B Impact Assessment. If the company answers affirmatively to any items in the Disclosure Questionnaire that B Lab deems relevant for public stakeholders, then, as a condition of their certification, the company must:

- Be transparent about details of the disclosure issues identified on the company's public B Impact Report
- 2) Describe how the company has addressed this issue
- 3) Demonstrate that management practices are in place to avoid similar issues from arising in the future, when necessary.

In all cases, the Standards Advisory council reserves the right to refuse certification if the company is ultimately deemed not to uphold the spirit and integrity of the community.

In addition to the voluntary indication of sensitive issues in the Disclosure Questionnaire, companies pursuing Certification also are subject to a background check by B Lab staff. Background checks include a review of public records, news sources, and search engines for company names, brands, executives/founders, and other relevant topics.

Sensitive issues identified through background checks may or may not be within the scope of questions in the Disclosure Questionnaire, but undergo the same review process and are subject to the same possible review by the Standards Advisory Council, including ineligibility for B Corp Certification, required remediation, or disclosure.

This document contains a copy of the company's completed Disclosure Questionnaire and related disclosure documentation provided by the company



Disclosure Questionnaire

Industries and Products

Yes No Please indicate if the company is involved in production of or trade in any of the following. Select Yes for all options that **Animal Products or Services** $\boxed{}$ **Biodiversity Impacts** Chemicals $\boxed{}$ **Disclosure Alcohol Disclosure Firearms Weapons** $\boxed{}$ **Disclosure Mining** $\boxed{}$ **Disclosure Pornography** $\boxed{}$ **Disclosure Tobacco** $\boxed{}$ **Energy and Emissions Intensive** $\boxed{}$ Industries Fossil fuels \square Gambling **Genetically Modified Organisms** $\boxed{}$ Illegal Products or Subject to $\boxed{}$ **Phase Out** Industries at Risk of Human \square **Rights Violations Monoculture Agriculture** \square **Nuclear Power or Hazardous** $\overline{\mathbf{A}}$ **Materials** Payday, Short Term, or High **Interest Lending Water Intensive Industries** $\overline{\mathbf{A}}$ Tax Advisory Services

Outcomes & Penalties

	Yes	No	
Please indicate if the company has had any formal complaint to a regulatory agency or been assessed any fine or sanction in the past five years for any of the following practices or policies. Check all that apply.			
Anti-Competitive Behavior		V	
Breaches of Confidential Information		N	
Bribery, Fraud, or Corruption		V	
Company has filed for bankruptcy		V	
Consumer Protection		V	
Financial Reporting, Taxes, Investments, or Loans		V	
Hazardous Discharges Into Air/Land/Water (Past 5 Yrs)		V	
Labor Issues		V	
Large Scale Land Conversion, Acquisition, or Relocation		N	
Litigation or Arbitration		V	
On-Site Fatality		\searrow	
Penalties Assessed For Environmental Issues		V	
Political Contributions or International Affairs		V	
Recalls		V	
Significant Layoffs		V	
Violation of Indigenous Peoples Rights		V	
Other		\checkmark	



Practices

	Yes	No	
Please indicate if the following statements are true regarding whether or not the company engages in the following practices. Check all that apply. If the statement is true, select "Yes." If false, select "No."			
Animal Testing		\checkmark	
Company/Suppliers Employ Under Age 15 (Or Other ILO Minimum Age)		\vee	
Company prohibits freedom of association/collective bargaining		\checkmark	
Company workers are prisoners		\checkmark	
Conduct Business in Conflict Zones		\checkmark	
Confirmation of Right to Work		\checkmark	
Does not transparently report corporate financials to government		\searrow	
Employs Individuals on Zero-Hour Contracts		V	
Facilities located in sensitive ecosystems		V	
ID Cards Withheld or Penalties for Resignation		V	
No formal Registration Under Domestic Regulations		V	
No signed employment contracts for all workers			
Overtime For Hourly Workers Is Compulsory		V	
Payslips not provided to show wage calculation and deductions		V	

	Yes	No
Sale of Data		V
Tax Reduction Through Corporate Shells		V
Workers cannot leave site during non-working hours		V
Workers not Provided Clean Drinking Water or Toilets		\searrow
Workers paid below minimum wage		\vee
Workers Under Bond		\checkmark
Other	\checkmark	

Supply Chain Disclosures

	Yes	No
Please indicate if any of the following statements are true regarding your company's significant suppliers.		
Business in Conflict Zones		V
Child or Forced Labor		V
Negative Environmental Impact		\vee
Negative Social Impact		\checkmark
Other		\checkmark



Disclosure Questionnaire Statement

Disclosure Questionnaire Category: Others - Clients in Controversial Industries

Issue Date	2021 - 2022
Topic	Company serves clients in Controversial Industries - Pharmaceuticals.
Summary of Issue	MiyaHealth provided Bioton with a white-label diabetes management platform that diabetic patients use to monitor their health status and that proactively informs patients of healthcare engagements (e.g., when to see their doctor next, alert when their blood sugar is too high, etc.).
Size/Scope of Issue (e.g. \$ financial implication, # of individuals affected)	70% in 2021 and 50% in 2022 of MiyaHealth's revenue has been from 1 client in the pharmaceutical industry.
Impact on Stakeholders	Companies that offer products/services to clients in controversial industries may be contributing to the controversial impact of those industries.
Management Practices	The company maintains an open stance toward the pharmaceutical industry. While they don't actively pursue these clients, they have established a dedicated risk assessment team, rigorous due diligence processes, a robust compliance framework, regular audits, and internal controls to guide collaborations with pharmaceutical clients and ensure risks are mitigated. They also engage in active industry research. Their first pharmaceutical client was an opportunistic case in the early commercialization stage of the company, leading to a significant share of revenue in 2021 and 2022. This client approached them to develop a diabetes management platform to complement the client's products, under a flat fee agreement. This collaboration prompted them to pursue ISO certification and have the platform (Miya Patient) CE Marked as a Class I medical device, thereby mitigating potential risks.
	Pharmaceutical companies aren't their primary focus, however they remain open to strategic opportunities, undertaking careful due diligence before considering engagement.